ASND Ascendis Pharma A/S
$245.49▲ +0.14%
Healthcare
Other
Volume 144.0K
Avg Volume (10D) 665.7K
Key Metrics & Fundamentals
Market Cap
$16.15B
P/E Ratio
18.8
Div Yield
0.00%
52W Range
188.07 - 282.15
% vs 50 MA
1.08%
% vs 200 MA
3.30%
RSI-14
61.0
MACD Histogram
+3.1100
Beta (1Y vs SPY)
0.28
Free Cash Flow
$270.73M
Gross Rev
$339.29M
Gross Profit
$311.63M
EBITDA
$242.01M
COGS
$27.66M
Operating Exp
$91.16M
Operating Income
$220.47M
EBIT
$220.47M
Pretax Income
$230.09M
Net Income
$206.97M
EPS (Diluted)
2.83
Price & Volume History
Loading chart…
Recent News
Ascendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with Hypoparathyroidism
MT Newswires · Oct 26, 2026 9:31 AM ET
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
GlobeNewswire · Oct 26, 2026 8:00 AM ET
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
Zacks · Oct 21, 2026 7:00 AM ET
RBC Capital names top healthcare stocks as sector upgraded to overweight
Investing.com · Oct 20, 2026 3:27 PM ET
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
Stocktwits · Oct 16, 2026 4:30 PM ET
Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia
MT Newswires · Oct 16, 2026 8:58 AM ET
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
GlobeNewswire · Oct 16, 2026 8:29 AM ET
UBS Adjusts Ascendis Pharma A/S Price Target to $269 From $307, Maintains Buy Rating
MT Newswires · Oct 15, 2026 10:33 AM ET
Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update
Business Wire · Oct 14, 2026 1:50 PM ET
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
Zacks · Oct 7, 2026 10:37 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ASND's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.